Cell Immunotherapy CRO Services
From antibody discovery to in vivo validation, Cyagen delivers an end-to-end solution for immune cell therapy R&D — supporting CAR-T, CAR-NK, and universal cell therapies with customizable services spanning antibody development, CAR vector design, cell engineering, and efficacy testing to empower breakthroughs in oncology and beyond.
One-Stop Autoimmune & Inflammation CRO Solutions
Cyagen provides one-stop CRO solutions for autoimmune and inflammation drug discovery,
offering both genetically engineered and induced disease models alongside full-spectrum in vivo and in vitro
efficacy services. With extensive experience in modeling RA, SLE, IBD, and other disorders, our platform
supports both basic research and translational studies — delivering data-driven insights for IND submissions and
therapeutic innovation.
{{ item.title }}
{{static_tabs[0].title}}
Antibody Discovery for CAR Constructs
Dual Strategies for scFv Generation – Built for Flexibility
Whether your research calls for a robust in vivo immune response or
high-throughput in vitro selection, Cyagen provides two complementary approaches to antibody
generation for CAR molecule design. Choose from HUGO-Ab™ fully human antibody mice for natural
repertoire development, or our phage display libraries for rapid screening of high-affinity binders
— both backed by expert validation and seamless CAR construct integration.
{{ item.label }}
{{v2.label}}
{{item.context}}
{{v2.context}}
{{static_tabs[1].title}}
CAR Molecule Design & Vector Engineering
Tailor Your CAR Construct with Confidence
Cyagen provides comprehensive support for chimeric antigen receptor (CAR)
molecule design and lentiviral vector construction. From scFv integration to co-stimulatory domain
selection and reporter tagging, our team helps you develop functional, customizable
Key Capabilities:
- Modular CAR Design: scFv screening and optimization, hinge/transmembrane/co-stimulatory domain selection (e.g., CD28, 4-1BB)
- Vector Construction: Gene synthesis and subcloning into 3rd-generation lentiviral backbones
- CAR Reporter Integration: Optional GFP, RFP, or luciferase tagging for expression validation
- Ready-to-Use Plasmid Libraries: Available constructs targeting CD19, GPC3, BCMA, HER2, etc.
Figure 1. Modular Structure of a CAR Molecule
Figure 2. Lentiviral Vector Map for CAR
Expression
Deliverables:
- Vector maps and sequence files
- CAR expression plasmids
- Lentiviral packaging-ready constructs
- QC report on vector integrity and CAR cassette structure
{{static_tabs[2].title}}
Immune Cell Preparation
Engineered for Precision and Performance
Cyagen provides high-quality preparation of CAR-T, CAR-NK, and universal CAR-T
(UCAR-T) cells using standardized and customizable protocols. From primary cell isolation to CAR
transduction and expansion, every step is optimized to ensure high expression, p
Key Capabilities:
- T and CAR-T Cell Production: CD4/CD8-balanced populations with high viability and transduction efficiency
- NK and CAR-NK Cell Generation: High-activity innate effector cells suitable for allogeneic therapy
- Universal CAR-T Cell Engineering: TCRα/CD52 knockout with CRISPR and lentiviral transduction for GVHD-free UCAR-T cells
- Murine CAR-T Cells: For use in murine tumor models or immunological research
- Immortalized CAR Tool Cells: Jurkat, NK-92, and THP-1 engineered for CAR screening and assay standardization
Deliverables:
- Validated CAR+ immune cells (T, NK, UCAR-T, etc.)
- Cell purity and positivity reports
- Full experimental documentation
{{static_tabs[3].title}}
In Vitro Efficacy Evaluation
Functional Insights at Every Step
Cyagen’s in vitro assays provide robust pharmacological data to support the
evaluation of CAR-T, CAR-NK, UCAR-T, and related cell therapies. From cytotoxicity to cytokine
secretion, our in vitro services are designed to validate candidate potency, optimize dosing
strategies, and guide in vivo studies with confidence.
Key Capabilities:
- Cell Proliferation Assays: Quantify CAR cell expansion under various stimulatory conditions
- Cytotoxicity Assays: Co-culture with tumor cell lines to assess real-time killing activity
- Cytokine Release Profiling: Analyze secreted IFN-γ, TNF-α, IL-2 and others post-target engagement
- Phagocytosis Assays: Assess CAR-macrophage antibody-dependent cellular phagocytosis (ADCP)
- ADCC/ADCP Assays for Antibody Drugs: Evaluate immune effector function of mAbs with NK/macrophage models
Deliverables:
- Cell proliferation curves and viability metrics
- Cytotoxicity data with target cell killing efficiency
- Cytokine concentration results (ELISA or multiplex)
- Imaging or flow-based phagocytosis analysis
- Comprehensive experimental report
{{static_tabs[4].title}}
In Vivo Pharmacology
Translate Cell Function into Tumor Response
Cyagen offers comprehensive in vivo pharmacology solutions for evaluating
immune cell therapy efficacy in preclinical models. Our services span model selection, drug
administration, and multi-parameter efficacy assessment — enabling robust and reproducible
CDX & Syngeneic Tumor Models
Leverage our tumor cell line database and modeling expertise to assess
CAR-T/NK therapies in immunodeficient (e.g., NKG) or immunocompetent hosts.
→ Common models: subcutaneous, intravenous,
orthotopic implants
HIS (Human Immune System) Models
Use PBMC or HSC humanized mice to simulate human immune responses for
universal and allogeneic CAR cell products.
→ Long-window, high-homogeneity models with proven
engraftment performance
Drug Administration & Tumor Monitoring
Standardized protocols for:
- Immune cell infusion
- Tumor volume tracking (caliper or bioluminescence)
- Survival and body weight monitoring
Biochemical & Histological Analysis
Evaluate treatment efficacy through:
- Blood cytokine profiling (e.g., IFN-γ, IL-2)
- Tumor tissue histology and IHC
- Immune cell infiltration markers
Deliverables:
- Tumor growth curves, survival and body weight data
- Imaging data from bioluminescent/luciferase-labeled tumors
- Cytokine levels and immune cell infiltration analysis
- Full study report with statistical analysis and interpretation
Case Highlights
{{ item.label }}
{{v2.label}}
{{item.context}}
{{v2.context}}
Our Unique Advantages
End-to-End Customization Across Development Pipeline
From antibody discovery to in vivo validation, Cyagen offers modular services supporting CAR-T, CAR-NK, and universal therapies — accelerating development with seamless integration.
Proprietary Models & Toolkits for In Vivo Evaluation
Leverage our proprietary NKG mice, validated CDX/syngeneic tumor models, and HIS (PBMC/HSC) platforms for reproducible, translational in vivo data.
Robust Cell Engineering with GMP-Ready Workflows
We deliver high-purity, high-activity CAR-T/NK cells using optimized protocols — including TCRα/CD52 knockout and scalable lentiviral transduction — built for reliability and consistency.
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.